Citi upgraded Haemonetics (HAE) to Buy from Neutral with a price target of $90, up from $71. The firm believes the company’s path forward is “more derisked” following the fiscal 2026 guidance update. Haemonetics’ plasma share gains are not factored into contracts, which will support high-single-digit core revenue growth and high-teens earnings growth, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HAE: